Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments provides a balanced exploration of the dual roles of nanotechnologies in oncology. Structured in four parts, the book begins with foundational knowledge of nanovaccines and nanomedicines, detailing their applications in cancer care and highlighting their precision in targeting cancer cells while reducing systemic toxicity. Importantly, the book addresses potential drawbacks, discussing side effects and safety concerns associated with these innovations. The final section emphasizes ethical, regulatory, and safety challenges, underscoring the need for careful oversight as nanotechnologies advance.
For the academic audience, this book serves as a vital resource, offering insights that equip researchers and healthcare professionals to make informed decisions regarding clinical applications. Its focus on both benefits and risks, alongside forward-looking perspectives, ensures that readers are well-prepared for future developments in the field of nanomedicine and cancer therapy.
1. Chapter 1. Introduction to nanovaccines - p. 3 2. Chapter 2. Introduction to nanomedicine in cancer treatments - p. 19 3. Chapter 3. Sensors for cancer detection - p. 33 4. Chapter 4. Current perspectives of nanomedicines in cancer treatment - p. 47 5. Chapter 5. Current perspectives of nanovaccines and nanomedicines in cancer treatment - p. 63 6. Part 2: Advantage and application of nanovaccine and nanomedicine - p. P79 7. Chapter 6. Advantage of cancer nanomedicine - p. 81 8. Chapter 7. Advantages of targeted nanomedicine in cancer treatment - p. 95 9. Chapter 8. Current perspectives of nanovaccines in cancer treatment - p. 115 10. Chapter 9. Nanovaccines and nanomedicines in cancer treatment: current landscape - p. 133 11. Part 3: The other side of nanovaccine and nanomedicine - p. P149 12. Chapter 10. Side effects and toxicity of nanovaccine in cancer treatment - p. 151 13. Chapter 11. Side effect and toxicity of nanomedicine in cancer treatment - p. 165 14. Chapter 12. Crossing the barrier, crossing the line: neurotoxicity of nanomedicines in brain cancer therapy - p. 195 15. Chapter 13. Side effects and toxicity of nanoparticles in cancer treatment - p. 233 16. Chapter 14. Toxicity of metal oxide nanoparticles in nanomedicine—mechanisms and implications - p. 243 17. Chapter 15. Nanotoxicity, safety assessment, regulatory aspects, and clinical trial of nanovaccines/nanomedicine - p. 253 18. Chapter 16. Nanotoxicity and nano-genotoxicity in cancer care - p. 281 19. Chapter 17. Toxicity evaluation and management for nanoparticles in the cancer therapy - p. 295 20. Chapter 18. Nanoparticle toxicity in cancer nanomedicine - p. 303 21. Part 4: Challenge and perspectives - p. P325 22. Chapter 19. Nanomedicines and nanovaccines manufacturing - p. 327 23. Chapter 20. Ethics in nanomedicine and nanovaccine for cancer treatment - p. 355 24. Chapter 21. Ethics in cancer nanomedicine - p. 373 25. Chapter 22. Ethics and regulations in nanomedicines and nanovaccines - p. 383 26. Chapter 23. Regulating nanomedicine: challenges and opportunities - p. 401 27. Chapter 24. Safety assessment for nanomedicines and nanovaccines - p. 411 28. Chapter 25. Manufacturing nanomedicines and nanovaccines: challenges and issues - p. 443 29. Chapter 26. Future perspectives of nanovaccines and nanomedicines - p. 457 30. Index - p. 471
Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments provides a balanced exploration of the dual roles of nanotechnologies in oncology. Structured in four parts, the book begins with foundational knowledge of nanovaccines and nanomedicines, detailing their applications in cancer care and highlighting their precision in targeting cancer cells while reducing systemic toxicity. Importantly, the book addresses potential drawbacks, discussing side effects and safety concerns associated with these innovations. The final section emphasizes ethical, regulatory, and safety challenges, underscoring the need for careful oversight as nanotechnologies advance.
For the academic audience, this book serves as a vital resource, offering insights that equip researchers and healthcare professionals to make informed decisions regarding clinical applications. Its focus on both benefits and risks, alongside forward-looking perspectives, ensures that readers are well-prepared for future developments in the field of nanomedicine and cancer therapy.
1. Chapter 1. Introduction to nanovaccines - p. 3 2. Chapter 2. Introduction to nanomedicine in cancer treatments - p. 19 3. Chapter 3. Sensors for cancer detection - p. 33 4. Chapter 4. Current perspectives of nanomedicines in cancer treatment - p. 47 5. Chapter 5. Current perspectives of nanovaccines and nanomedicines in cancer treatment - p. 63 6. Part 2: Advantage and application of nanovaccine and nanomedicine - p. P79 7. Chapter 6. Advantage of cancer nanomedicine - p. 81 8. Chapter 7. Advantages of targeted nanomedicine in cancer treatment - p. 95 9. Chapter 8. Current perspectives of nanovaccines in cancer treatment - p. 115 10. Chapter 9. Nanovaccines and nanomedicines in cancer treatment: current landscape - p. 133 11. Part 3: The other side of nanovaccine and nanomedicine - p. P149 12. Chapter 10. Side effects and toxicity of nanovaccine in cancer treatment - p. 151 13. Chapter 11. Side effect and toxicity of nanomedicine in cancer treatment - p. 165 14. Chapter 12. Crossing the barrier, crossing the line: neurotoxicity of nanomedicines in brain cancer therapy - p. 195 15. Chapter 13. Side effects and toxicity of nanoparticles in cancer treatment - p. 233 16. Chapter 14. Toxicity of metal oxide nanoparticles in nanomedicine—mechanisms and implications - p. 243 17. Chapter 15. Nanotoxicity, safety assessment, regulatory aspects, and clinical trial of nanovaccines/nanomedicine - p. 253 18. Chapter 16. Nanotoxicity and nano-genotoxicity in cancer care - p. 281 19. Chapter 17. Toxicity evaluation and management for nanoparticles in the cancer therapy - p. 295 20. Chapter 18. Nanoparticle toxicity in cancer nanomedicine - p. 303 21. Part 4: Challenge and perspectives - p. P325 22. Chapter 19. Nanomedicines and nanovaccines manufacturing - p. 327 23. Chapter 20. Ethics in nanomedicine and nanovaccine for cancer treatment - p. 355 24. Chapter 21. Ethics in cancer nanomedicine - p. 373 25. Chapter 22. Ethics and regulations in nanomedicines and nanovaccines - p. 383 26. Chapter 23. Regulating nanomedicine: challenges and opportunities - p. 401 27. Chapter 24. Safety assessment for nanomedicines and nanovaccines - p. 411 28. Chapter 25. Manufacturing nanomedicines and nanovaccines: challenges and issues - p. 443 29. Chapter 26. Future perspectives of nanovaccines and nanomedicines - p. 457 30. Index - p. 471
